Explosive Growth Stock, a Serious Red Flag

Welcome back to Alpha Stocks Daily 👋

Every so often a stock lands on the watchlist that's genuinely exciting and genuinely dangerous — and the honest job is to give you both halves, because the exciting half is exactly what makes the dangerous half so easy to ignore. Today's pick is that stock. It has a real, FDA-approved cancer drug with sales growing ~90% a year. It also has an FDA warning letter, a stack of securities-fraud lawsuits, and a cash-burn problem. Miss either half and you'll misjudge the whole thing.

Today's ticker: ImmunityBio ($IBRX) — a commercial-stage immuno-oncology company built around a novel immune-activating platform. This is not a "safe" name. It's a high-risk, high-reward speculation, and today we're going to be blunt about the risk. Let's dig in. 👇

Investors are spending a lot of time trying to figure out which AI company is worth their time and money.

Should they bet on OpenAI? Anthropic? Or one of the many other large language models on the horizon?

But there may be a simpler way to invest in AI: the companies these platforms need to keep growing.

Each large language model requires a massive amount of specialized technology to stay up and running, including memory, storage, networking, semiconductor manufacturing, power, and cooling infrastructure.

MarketBeat’s new The Infrastructure’s Backbone: 10 Stocks Powering the AI Buildout report identifies 10 publicly traded companies that are crucial to the AI infrastructure buildout already underway.

These companies are building the underlying ecosystem that could power the next round of growth for the AI industry.

Get The 10 Names

Let's start with why anyone's interested. ImmunityBio's lead drug, ANKTIVA (an IL-15 superagonist that revs up the body's natural killer and T-cells), is FDA-approved for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) — a real, differentiated, approved product, not a science project. And the commercial ramp is legitimately impressive:

If you only read that, you'd be excited. So now let's read the rest.

Here's what a bullish write-up would conveniently skip. In March 2026, the FDA issued a formal Warning Letter to ImmunityBio over promotional claims about ANKTIVA. The trigger: founder and Executive Chairman Dr. Patrick Soon-Shiong, on a January podcast, claimed that although ANKTIVA is approved for bladder cancer, "it actually can treat all cancers." The FDA found the TV ad and podcast "false or misleading," warning that the materials "grossly misrepresent the benefits of ANKTIVA" and create the impression the drug can "cure and even prevent all cancer."

The fallout was severe and is ongoing:

This isn't a minor compliance footnote. It's a credibility and governance issue at the very top of the company — the person making the flagged claims is the controlling shareholder — and the litigation overhang won't clear quickly. Any responsible look at IBRX has to weigh this as heavily as the revenue growth.

The second hard truth: ImmunityBio is deeply unprofitable and burning cash. It posted a 2025 net loss of roughly $351M against ~$113M of revenue, and losses continued in 2026 (a Q2 net loss of around $0.22 per share). Revenue of ~$51M a quarter simply doesn't cover the commercialization spend and ongoing trials.

That math has one inevitable consequence: the company needs capital, repeatedly. With ~1.05 billion shares already outstanding — much of it tied to founder financing — dilution is a structural, recurring risk for anyone holding the stock. Growth is real, but so is the tab.

Coverage is thin and specialist-driven — appropriate for a name this speculative. Roughly 4–6 firms cover IBRX, leaning bullish, with an average 12-month target near $12.75 (~60% above the ~$7.85 price) and a very wide range (~$9 to ~$23). That spread — and the small analyst count — tells you this is a high-uncertainty stock, not a well-covered blue chip.

Note the tension: analysts model big upside, but recent options activity has skewed bearish and the stock is down ~7% on the week. When the pros are hedging while targets stay high, that's a market that hasn't made up its mind.

The honest read: this is a founder-controlled story, for better and worse — you're effectively betting on Soon-Shiong.

Context matters: IBRX gapped down hard on the March FDA news (to ~$7.42) and has been choppy and range-bound since, now around $7.85 and down ~7% on the week. This is a repairing chart, not a clean uptrend.

Let's be honest in both directions. The bull case is real: ImmunityBio has a genuine FDA-approved drug, revenue growing ~90% a year, and international momentum — the ingredients of a true clinical-to-commercial success story, and if ANKTIVA's label expands, the upside could be large. That's why analysts still target ~$12.75.

But this is not a "commercial powerhouse with a textbook setup." It's a speculative, high-risk biotech carrying a serious credibility cloud — an FDA warning over the founder's own "cures all cancer" claims, active fraud lawsuits, deep losses, and relentless dilution risk. Those aren't reasons to never look; they're reasons to size small and go in clear-eyed. The single most important thing to watch is credibility — whether management resolves the FDA issue and the litigation, and funds the business without crushing shareholders. If it does, today's price could look cheap. If the overhang deepens, this can fall a long way. A lottery-ticket-style speculation for risk-tolerant traders only — never a core holding, and never money you can't afford to lose.

What we're watching next: the FDA/litigation resolution, the cash runway and any financing (dilution), ANKTIVA label-expansion data, and Q3 results.

Trade smart, size your risk, and we'll see you tomorrow. 🧬